Zobrazeno 1 - 10
of 212
pro vyhledávání: '"David W, Cescon"'
Autor:
Seock-Ah Im, Javier Cortes, David W. Cescon, Mastura Md Yusof, Hiroji Iwata, Norikazu Masuda, Toshimi Takano, Chiun-Sheng Huang, Chi-Feng Chung, Koichiro Tsugawa, Yeon Hee Park, Koji Matsumoto, Kenichi Inoue, Ava Kwong, Sherene Loi, Wei Fu, Wilbur Pan, Vassiliki Karantza, Hope S. Rugo, Peter Schmid
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-9 (2024)
Abstract In the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus ch
Externí odkaz:
https://doaj.org/article/779d501670554a368c8218be67b35429
Autor:
Chang-Ching Lin, Tsung-Cheng Chang, Yunguan Wang, Lei Guo, Yunpeng Gao, Emmanuel Bikorimana, Andrew Lemoff, Yisheng V. Fang, He Zhang, Yanfeng Zhang, Dan Ye, Isabel Soria-Bretones, Alberto Servetto, Kyung-min Lee, Xuemei Luo, Joseph J. Otto, Hiroaki Akamatsu, Fabiana Napolitano, Ram Mani, David W. Cescon, Lin Xu, Yang Xie, Joshua T. Mendell, Ariella B. Hanker, Carlos L. Arteaga
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract CDK4/6 inhibitors (CDK4/6i) have improved survival of patients with estrogen receptor-positive (ER+) breast cancer. However, patients treated with CDK4/6i eventually develop drug resistance and progress. RB1 loss-of-function alterations conf
Externí odkaz:
https://doaj.org/article/e4a5c7d11ac44ac3ba09402a88d94d20
Autor:
Sierra Pellizzari, Vasudeva Bhat, Harjot Athwal, David W. Cescon, Alison L. Allan, Armen Parsyan
Publikováno v:
Radiation Oncology, Vol 19, Iss 1, Pp 1-8 (2024)
Abstract Radioresistance is one of the barriers to developing more effective therapies against the most aggressive, triple-negative, breast cancer (TNBC) subtype. In our previous studies, we showed that inhibition of Polo-like Kinase 4 (PLK4) by a no
Externí odkaz:
https://doaj.org/article/61c0db00737c4c9c86f1edbde2ca4845
Publikováno v:
Clinical and Translational Medicine, Vol 14, Iss 1, Pp n/a-n/a (2024)
Abstract Breast cancer arises from a series of molecular alterations that disrupt cell cycle checkpoints, leading to aberrant cell proliferation and genomic instability. Targeted pharmacological inhibition of cell cycle regulators has long been consi
Externí odkaz:
https://doaj.org/article/03bb5f328ae6495b81eedd820a3bcf93
Autor:
Hyeyeon Kim, Kazeera Aliar, Pirashaanthy Tharmapalan, Curtis W. McCloskey, Abhijith Kuttanamkuzhi, Barbara T. Grünwald, Luis Palomero, Mathepan J. Mahendralingam, Matthew Waas, Arvind S. Mer, Mitchell J. Elliott, Bowen Zhang, Khalid N. Al-Zahrani, Ellen R. Langille, Michael Parsons, Swami Narala, Stefan Hofer, Paul D. Waterhouse, Razqallah Hakem, Benjamin Haibe-Kains, Thomas Kislinger, Daniel Schramek, David W. Cescon, Miquel A. Pujana, Hal K. Berman, Rama Khokha
Publikováno v:
Cell Reports, Vol 42, Iss 11, Pp 113382- (2023)
Externí odkaz:
https://doaj.org/article/7cdadbe68d5c48a4b19b8899301c9920
Autor:
Jenna E. van Leeuwen, Wail Ba-Alawi, Emily Branchard, Jennifer Cruickshank, Wiebke Schormann, Joseph Longo, Jennifer Silvester, Peter L. Gross, David W. Andrews, David W. Cescon, Benjamin Haibe-Kains, Linda Z. Penn, Deena M. A. Gendoo
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
Statins are promising for breast cancer therapy; dipyridamole can potentiate their effects, but is contraindicated in some cases. Here, the authors develop a pharmacogenomics pipeline to predict other compounds that potentiate statins, and validate t
Externí odkaz:
https://doaj.org/article/f57984f909454f0787ee786ab65589d9
Autor:
John Hilton, Karen Gelmon, Philippe L. Bedard, Dongsheng Tu, Hong Xu, Anna V. Tinker, Rachel Goodwin, Scott A. Laurie, Derek Jonker, Aaron R. Hansen, Zachary W. Veitch, Daniel J. Renouf, Linda Hagerman, Hongbo Lui, Bingshu Chen, Deb Kellar, Irene Li, Sung-Eun Lee, Takako Kono, Brian Y. C. Cheng, Damian Yap, Daniel Lai, Sean Beatty, John Soong, Kathleen I. Pritchard, Isabel Soria-Bretones, Eric Chen, Harriet Feilotter, Moira Rushton, Lesley Seymour, Samuel Aparicio, David W. Cescon
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
G-quadruplex stabilizers, including CX-5461, exhibit synthetic lethality with loss of BRCA1/2 in preclinical models. Here the authors report the results of a phase I study of CX-5461 in patients with solid tumors enriched for DNA-repair deficiencies.
Externí odkaz:
https://doaj.org/article/ee095627571b4e258e1890f77d3d7597
Publikováno v:
Frontiers in Genetics, Vol 14 (2023)
Triple negative breast cancer (TNBC) has poor prognosis when compared to other breast cancer subtypes. Despite pre-clinical data supporting an immune targeted approach for TNBCs, immunotherapy has failed to demonstrate the impressive responses seen i
Externí odkaz:
https://doaj.org/article/3732e2ef3e5e4c62bae60e82491369e7
Autor:
Elisabeth Prince, Jennifer Cruickshank, Wail Ba-Alawi, Kelsey Hodgson, Jillian Haight, Chantal Tobin, Andrew Wakeman, Alona Avoulov, Valentina Topolskaia, Mitchell J. Elliott, Alison P. McGuigan, Hal K. Berman, Benjamin Haibe-Kains, David W. Cescon, Eugenia Kumacheva
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-12 (2022)
Patient-derived tumour organoids are important preclinical models but suffer from variability from the use of basement-membrane extract and cell contamination. Here, the authors report on the development of mimetic nanofibrilar hydrogel which support
Externí odkaz:
https://doaj.org/article/dda5710243f944a48c6092025f6d253a
Autor:
Jesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, Igor López-Cade, Víctor Lorca, Alejandro Pascual, Alicia de Luna, Carmen Ramírez-Ruda, Jennifer Swindell, Paloma Flores, Ana Lluch, David W. Cescon, Pedro Pérez-Segura, Alberto Ocaña, Frederick Jones, Fernando Moreno, Vanesa García-Barberán, José Ángel García-Sáenz
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 14, p 11419 (2023)
Endocrine-resistant, hormone receptor-positive, and HER2-negative (HR+/HER2-) metastatic breast cancer (mBC) is largely governed by acquired mutations in the estrogen receptor, which promote ligand-independent activation, and by truncal alterations i
Externí odkaz:
https://doaj.org/article/ad6deb7e9e48410696732803de1a58c1